News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
346,021 Results
Type
Article (19704)
Company Profile (95)
Press Release (326215)
Multimedia
Podcasts (35)
Webinars (6)
Section
Business (89477)
Career Advice (1339)
Deals (17558)
Drug Delivery (65)
Drug Development (61423)
Employer Resources (62)
FDA (9175)
Job Trends (7564)
News (174908)
Policy (15281)
Tag
Academia (1220)
Academic (1)
Accelerated approval (11)
Adcomms (15)
Allergies (92)
Alliances (17885)
ALS (98)
Alzheimer's disease (1081)
Antibody-drug conjugate (ADC) (167)
Approvals (9344)
Artificial intelligence (202)
Autoimmune disease (62)
Automation (11)
Bankruptcy (139)
Best Places to Work (6370)
BIOSECURE Act (8)
Biosimilars (102)
Biotechnology (59)
Bladder cancer (110)
Brain cancer (38)
Breast cancer (452)
Cancer (3141)
Cardiovascular disease (255)
Career advice (1066)
Career pathing (19)
CAR-T (146)
CDC (14)
Cell therapy (386)
Cervical cancer (23)
Clinical research (53546)
Collaboration (706)
Company closure (1)
Compensation (398)
Complete response letters (21)
COVID-19 (2275)
CRISPR (38)
C-suite (212)
Cystic fibrosis (92)
Data (4100)
Denatured (1)
Depression (64)
Diabetes (375)
Diagnostics (3485)
Digital health (16)
Diversity (2)
Diversity, equity & inclusion (8)
Drug discovery (108)
Drug pricing (76)
Drug shortages (23)
Duchenne muscular dystrophy (126)
Earnings (55210)
Editorial (23)
Employer branding (11)
Employer resources (53)
Events (55894)
Executive appointments (321)
FDA (11054)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (7)
Funding (734)
Gene editing (85)
Generative AI (14)
Gene therapy (308)
GLP-1 (803)
Government (2467)
Grass and pollen (6)
Guidances (352)
Healthcare (9677)
HIV (38)
Huntington's disease (26)
IgA nephropathy (53)
Immunology and inflammation (164)
Immuno-oncology (10)
Indications (50)
Infectious disease (2420)
Inflammatory bowel disease (123)
Inflation Reduction Act (5)
Influenza (70)
Intellectual property (127)
Interviews (245)
IPO (10239)
IRA (20)
Job creations (1470)
Job search strategy (914)
Kidney cancer (16)
Labor market (49)
Layoffs (291)
Leadership (21)
Legal (2494)
Liver cancer (60)
Longevity (7)
Lung cancer (476)
Lymphoma (242)
Machine learning (11)
Management (17)
Manufacturing (281)
MASH (120)
Medical device (6509)
Medtech (6522)
Mergers & acquisitions (7865)
Metabolic disorders (909)
Multiple sclerosis (109)
NASH (17)
Neurodegenerative disease (143)
Neuropsychiatric disorders (39)
Neuroscience (1798)
NextGen: Class of 2025 (2662)
Non-profit (1853)
Now hiring (18)
Obesity (441)
Opinion (116)
Ovarian cancer (111)
Pain (119)
Pancreatic cancer (135)
Parkinson's disease (185)
Partnered (15)
Patents (219)
Patient recruitment (248)
Peanut (41)
People (15965)
Pharmaceutical (28)
Pharmacy benefit managers (7)
Phase I (15193)
Phase II (26359)
Phase III (17269)
Pipeline (2374)
Policy (89)
Postmarket research (1587)
Preclinical (5119)
Press Release (30)
Prostate cancer (156)
Psychedelics (32)
Radiopharmaceuticals (161)
Rare diseases (432)
Real estate (1758)
Recruiting (30)
Regulatory (12733)
Reports (37)
Research institute (1182)
Resumes & cover letters (258)
Rett syndrome (16)
RNA editing (3)
RSV (44)
Schizophrenia (104)
Series A (103)
Series B (89)
Service/supplier (6)
Sickle cell disease (57)
Special edition (19)
Spinal muscular atrophy (134)
Sponsored (26)
Startups (1354)
State (2)
Stomach cancer (14)
Supply chain (46)
Tariffs (41)
The Weekly (34)
Vaccines (637)
Venture capital (27)
Weight loss (296)
Women's health (31)
Worklife (12)
Date
Today (173)
Last 7 days (635)
Last 30 days (2037)
Last 365 days (20684)
2025 (17389)
2024 (22018)
2023 (24445)
2022 (29984)
2021 (32062)
2020 (30534)
2019 (22702)
2018 (17293)
2017 (17517)
2016 (15334)
2015 (18685)
2014 (13373)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (413)
Alabama (42)
Alaska (1)
Arizona (88)
Arkansas (4)
Asia (22451)
Australia (4026)
California (6112)
Canada (1843)
China (668)
Colorado (228)
Connecticut (296)
Delaware (191)
Europe (50102)
Florida (828)
Georgia (206)
Hawaii (1)
Idaho (27)
Illinois (379)
India (29)
Indiana (285)
Iowa (12)
Japan (249)
Kansas (54)
Kentucky (28)
Louisiana (11)
Maine (38)
Maryland (739)
Massachusetts (4432)
Michigan (130)
Minnesota (273)
Mississippi (4)
Missouri (61)
Montana (14)
Nebraska (7)
Nevada (67)
New Hampshire (40)
New Jersey (1834)
New Mexico (4)
New York (1755)
North Carolina (671)
North Dakota (3)
Northern California (2870)
Ohio (148)
Oklahoma (1)
Oregon (18)
Pennsylvania (1201)
Puerto Rico (18)
Rhode Island (17)
South America (569)
South Carolina (14)
Southern California (2456)
Tennessee (58)
Texas (950)
United States (21447)
Utah (155)
Virginia (117)
Washington D.C. (39)
Washington State (490)
West Virginia (1)
Wisconsin (41)
346,021 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival
October 10, 2025
·
6 min read
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024.
October 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025
September 2, 2025
·
9 min read
Press Releases
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046) FDA issues Biologics Licensing Application (BLA) number for OST-HER2 in preparation for anticipated BLA filing for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma following August 27, 2025 End of Phase 2 Meeting Company responds to FDA correspondences seeking to align approval metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy designation (BTD) and Biologics Licensing Application via Accelerated Approval Program Company’s NYSE American listing included in the Russell Microcap, Russell Microcap Value and Russell Microcap Growth indexes
August 7, 2025
·
5 min read
Press Releases
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer
November 5, 2025
·
5 min read
Press Releases
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
September 18, 2025
·
5 min read
Press Releases
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
November 4, 2025
·
7 min read
Press Releases
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
October 16, 2025
·
7 min read
Press Releases
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
September 19, 2025
·
5 min read
Press Releases
ENHERTU® approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or more endocrine therapies
October 30, 2025
·
9 min read
1 of 34,603
Next
